GlassScriptPhysician profile
Carla Branch
NPI 1851394969
$9,273.94
in general payments reported to CMS, 2019-2025
52 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $1,075 · 2021: $1,414 · 2022: $1,523 · 2023: $1,796 · 2024: $1,434 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,660.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $941.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $848.89 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $712.84 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $579.59 | 2019-2025 | |
| Amgen INC. | $542.53 | 2019-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $537.47 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $537.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $333.60 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $285.18 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $277.88 | 2019-2025 | Trintellix |
| Esperion Therapeutics, INC. | $267.05 | 2020-2024 | Nexletol |
| Lundbeck LLC | $212.12 | 2023-2025 | Rexulti |
| Tris Pharma INC | $207.51 | 2022-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $204.72 | 2022-2025 | Rexulti |
| Dexcom, INC. | $198.72 | 2021-2025 | Dexcom G6 Transmitter |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.